Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy

ClinicalTrials.gov ID: NCT02891850

Public ClinicalTrials.gov record NCT02891850. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 23, 2026, 9:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Prospective, Randomized, International, Multicenter, Double-arm, Controlled, Open-label Study of Riociguat in Patients With Pulmonary Arterial Hypertension (PAH) Who Are on a Stable Dose of Phosphodiesterase-5 Inhibitors (PDE-5i) With or Without Endothelin Receptor Antagonist (ERA), But Not at Treatment Goal

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

To demonstrate the effectiveness of riociguat as replacement of phosphodiesterase-5 inhibitors (PDE-5i) therapy in pulmonary arterial hypertension (PAH) patients

Study identification

NCT ID: NCT02891850
Recruitment status: Completed
Study type: Interventional
Phase: Phase 4
Lead sponsor: Bayer; Industry
Enrollment: 225 participants

Conditions and interventions

Conditions

Pulmonary Arterial Hypertension

Interventions

Drug

Eligibility (public fields only)

Age range: 18 Years to 75 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jan 11, 2017 (Actual)
Primary completion: Jan 29, 2020 (Actual)
Completion: Mar 3, 2020 (Actual)
Last update posted: Feb 26, 2021

2017 – 2020

United States locations

U.S. sites: 17
U.S. states: 12
U.S. cities: 17

Facility	City	State	ZIP	Site status
Not listed	Phoenix	Arizona	85012	—
Not listed	Tucson	Arizona	85724	—
Not listed	Sacramento	California	95817	—
Not listed	Orlando	Florida	32803	—
Not listed	Weston	Florida	33331	—
Not listed	Kansas City	Kansas	66103	—
Not listed	Louisville	Kentucky	40202	—
Not listed	Detroit	Michigan	48202	—
Not listed	Troy	Michigan	48085	—
Not listed	Newark	New Jersey	07112	—
Not listed	Mineola	New York	11501	—
Not listed	New York	New York	10003	—
Not listed	Rochester	New York	14623	—
Not listed	Cleveland	Ohio	44195	—
Not listed	Nashville	Tennessee	37232	—
Not listed	Dallas	Texas	75390	—
Not listed	Richmond	Virginia	23225	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 64 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02891850, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 26, 2021 · Synced Oct 23, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02891850 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →